BMY
Bristol-Myers Squibb Co.

20,522
Mkt Cap
$95.05B
Volume
9.01M
52W High
$63.33
52W Low
$42.52
PE Ratio
15.77
BMY Fundamentals
Price
$46.72
Prev Close
$46.63
Open
$46.72
50D MA
$45.25
Beta
0.29
Avg. Volume
17.84M
EPS (Annual)
-$4.41
P/B
5.12
Rev/Employee
$1.42M
Loading...
Loading...
News
all
press releases
Resona Asset Management Co. Ltd. Grows Stock Holdings in Bristol Myers Squibb Company $BMY
Resona Asset Management Co. Ltd. raised its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 6.2% in the 2nd quarter, according to the company in its most recent disclosure with...
MarketBeat·2h ago
News Placeholder
More News
News Placeholder
Bristol Myers Squibb (NYSE:BMY) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Saturday...
MarketBeat·6h ago
News Placeholder
Validea Detailed Fundamental Analysis - BMY
Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Earnings Yield Investor model based on the published...
Nasdaq News: Markets·17h ago
News Placeholder
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
Zacks·22h ago
News Placeholder
Bristol Myers Squibb Company $BMY Holdings Raised by Sienna Gestion
Sienna Gestion grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 9.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·1d ago
News Placeholder
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Zacks·3d ago
News Placeholder
BMY CEO Expects Cancer Drug Opdivo To Drive Strong Sales In 2025
The company has increased its adjusted revenue outlook to a range of approximately $47.5 billion to $48.0 billion, up from a previous range of roughly $46.5 billion to $47.5 billion.
Stocktwits·9d ago
News Placeholder
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.
Zacks·9d ago
News Placeholder
Bristol Myers (BMY) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·9d ago
News Placeholder
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates
Bristol Myers (BMY) delivered earnings and revenue surprises of +10.14% and +3.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago

Latest BMY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.